Bortezomib/Liposomal doxorubicin (V-DD) is preferred to bortezomib single agent in salvage
therapy for Multiple Myeloma (MM).
The present study is designed to assessment the efficacy and safety study of Bortezomib in
combination with Liposomal Doxorubicin and Dexamethasone in treatment of Plasma Cell Leukemia
Primary study endpoint is the overall response rate (sCR+CR+VGPR+PR). Secondary endpoints is
the rate of complete response (sCR+CR), partial remission rate (VGPR + PR), duration of
response (DOR), overall survival (OS).